Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Visualizing extracellular vesicles in cancer: from biogenesis to theranostic applications

Deng D., Deng D., Wang L., Zeng Z., Lu L., Yang M.

Narrative Review on Immune Modulation, published in J Nanobiotechnology (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
J Nanobiotechnology (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41776618
PMCID
PMC13067413
DOI
10.1186/s12951-026-04223-6

Abstract (original English)

Within the complex landscape of the tumor microenvironment(TME), extracellular vesicles(EVs) function as sophisticated nanoscale signaling hubs that govern the intercellular crosstalk driving metastatic progression and immune modulation. Despite their burgeoning potential as next-generation biomarkers and biocompatible nanocarriers, the clinical translation of EVs is currently impeded by an incomplete elucidation of their complex spatiotemporal kinetics in vivo. This review provides a critical synthesis of the EV pipeline, from microenvironment-modulated biogenesis to advanced theranostic applications. We begin by analyzing how specific microenvironmental cues, such as hypoxia, acidosis, and radiation, modulate the cargo and surface markers of EVs to reveal new opportunities for bioengineering. Subsequently, we critically evaluate current isolation strategies and, more importantly, label-based and label-free imaging modalities, comparing their resolution and sensitivity for tracking EV biodistribution in real-time. Finally, we discuss the integration of these imaging technologies with therapeutic strategies, highlighting the transition of EVs from biological entities to engineered nanomedicines for liquid biopsy and targeted delivery. By identifying current technical bottlenecks in quantification and off-target labeling, we propose an integrated roadmap to accelerate the clinic

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsHumansNeoplasmsTumor MicroenvironmentExtracellular VesiclesTheranostic Nanomedicine

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research